JP2024525614A5 - - Google Patents
Info
- Publication number
- JP2024525614A5 JP2024525614A5 JP2024500493A JP2024500493A JP2024525614A5 JP 2024525614 A5 JP2024525614 A5 JP 2024525614A5 JP 2024500493 A JP2024500493 A JP 2024500493A JP 2024500493 A JP2024500493 A JP 2024500493A JP 2024525614 A5 JP2024525614 A5 JP 2024525614A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- complex according
- seq
- mstn
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220085P | 2021-07-09 | 2021-07-09 | |
| US202163220056P | 2021-07-09 | 2021-07-09 | |
| US202163220071P | 2021-07-09 | 2021-07-09 | |
| US202163220050P | 2021-07-09 | 2021-07-09 | |
| US202163220039P | 2021-07-09 | 2021-07-09 | |
| US63/220,039 | 2021-07-09 | ||
| US63/220,071 | 2021-07-09 | ||
| US63/220,085 | 2021-07-09 | ||
| US63/220,050 | 2021-07-09 | ||
| US63/220,056 | 2021-07-09 | ||
| PCT/US2022/073362 WO2023283531A2 (en) | 2021-07-09 | 2022-07-01 | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525614A JP2024525614A (ja) | 2024-07-12 |
| JP2024525614A5 true JP2024525614A5 (enExample) | 2025-07-09 |
Family
ID=84802048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500493A Pending JP2024525614A (ja) | 2021-07-09 | 2022-07-01 | 筋標的化複合体および筋肉の健康に関連する遺伝子の調整のためのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240382513A1 (enExample) |
| EP (1) | EP4366774A4 (enExample) |
| JP (1) | JP2024525614A (enExample) |
| CA (1) | CA3226361A1 (enExample) |
| WO (1) | WO2023283531A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4169576A1 (en) | 2018-03-23 | 2023-04-26 | University of Massachusetts | Gene therapeutics for treating bone disorders |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4185320A4 (en) * | 2020-07-23 | 2025-10-08 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2024220758A1 (en) * | 2023-04-20 | 2024-10-24 | University Of Massachusetts | Rnas targeting activin a subunits |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| CA2644046A1 (en) * | 2006-02-28 | 2007-09-07 | Trustees Of Boston University | Metabolic regulators and uses thereof |
| WO2011087091A1 (ja) * | 2010-01-15 | 2011-07-21 | 協和発酵キリン株式会社 | 抗システムａｓｃアミノ酸トランスポーター２（ａｓｃｔ２）抗体 |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| JP6976322B2 (ja) * | 2016-10-10 | 2021-12-08 | クラウン バイオサイエンス，インコーポレイテッド（タイツァン） | 新規抗ｃｔｌａ４抗体 |
| UY37523A (es) * | 2016-12-15 | 2018-07-31 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos |
| PE20210125A1 (es) * | 2017-10-14 | 2021-01-19 | Abbvie Inc | Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos |
| AU2019315593B2 (en) * | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| WO2020028832A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108328A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva |
| EP4185320A4 (en) * | 2020-07-23 | 2025-10-08 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
-
2022
- 2022-07-01 EP EP22838534.0A patent/EP4366774A4/en active Pending
- 2022-07-01 US US18/577,382 patent/US20240382513A1/en active Pending
- 2022-07-01 JP JP2024500493A patent/JP2024525614A/ja active Pending
- 2022-07-01 WO PCT/US2022/073362 patent/WO2023283531A2/en not_active Ceased
- 2022-07-01 CA CA3226361A patent/CA3226361A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535444A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2021533200A5 (enExample) | ||
| JP2021532832A5 (enExample) | ||
| JP7447073B2 (ja) | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド | |
| JP2024546436A5 (enExample) | ||
| JP2021533199A5 (enExample) | ||
| JP2023510351A5 (enExample) | ||
| JP2024501872A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| JP2023512442A5 (enExample) | ||
| JP2023535074A5 (enExample) | ||
| JP4118348B2 (ja) | Ｇキャプ安定化したオリゴヌクレオチド | |
| CA2564616C (en) | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | |
| JP2024524222A5 (enExample) | ||
| JP2024503609A5 (enExample) | ||
| JP2021533198A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| KR20210005068A (ko) | 고콜레스테롤혈증 및 관련 상태를 치료하기 위한 pcsk9 표적화 올리고뉴클레오티드 | |
| KR101605932B1 (ko) | Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물 | |
| JP2024539596A5 (enExample) | ||
| RS61529B1 (sr) | Oligonukleotidi za indukovanje ekspresije paternalnog ube3a | |
| JPH10510992A (ja) | 安定化リボザイムアナログ |